Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy

R. Sciuto, A. Festa, A. Tofani, R. Pasqualoni, A. Semprebene, R. Cucchi, A. Ferraironi, S. Rea, C. L. Maini

Research output: Contribution to journalArticle

Abstract

Purpose: Strontium-89 is currently used for the treatment of painful bone metastases. This study reports on two preliminary experiences with low- dose platinum compounds, carboplatin and cisplatin, as radiosensitizers in 89Sr therapy. Patients and Methods: 30 patients entered the carboplatin study: 15 patients (Group A) were treated with 148 MBq 89Sr followed by carboplatin (100 mg/m2 at 7 and 21 days) and 15 patients (Group B) were treated with 89Sr alone. 12 patients entered the cisplatin study: six patients (Arm 1) received 148 Mq 89Sr plus cisplatin (50 mg/m2) in two administrations (immediately before and 10 days after 89Sr injection) and six patients (Arm 2) received 89Sr plus two placebo administrations. Pain response was assessed 8 weeks after the therapy on the Wisconsin score modifications. Results: No clinically significant adverse effects or myelosuppression by platinum compounds were observed. In carboplatin study a pain response was observed in 20 of 27 (74%) evaluable patients, 13/15 in group A and 7/12 in group B. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). In cisplatin study a pain response was observed in 10 of 12 (83%) evaluable patients, 5/6 in Arm 1 and 4/6 in Arm 2. Conclusions: Low-dose platinum compounds seem to enhance the effects of 89Sr radioisotope therapy on pain from bone metastases without relevant hematological toxicity.

Original languageEnglish
Pages (from-to)43-47
Number of pages5
JournalClinica Terapeutica
Volume149
Issue number1
Publication statusPublished - Jan 1998

Keywords

  • Sr
  • Bone metastases
  • Compounds
  • Platinum
  • Radiosensitizers

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy'. Together they form a unique fingerprint.

  • Cite this

    Sciuto, R., Festa, A., Tofani, A., Pasqualoni, R., Semprebene, A., Cucchi, R., Ferraironi, A., Rea, S., & Maini, C. L. (1998). Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clinica Terapeutica, 149(1), 43-47.